These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 6213319)

  • 21. An overview of clinical trials with high-dose medroxyprogesterone acetate (HD-MPA) in endocrine-related tumors other than breast cancer.
    Robustelli della Cuna G; Zanon P; Pavesi L; Preti P; Prada GA; Decensi A
    Chemioterapia; 1986 Jun; 5(3):164-72. PubMed ID: 2941173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The bioavailability of an orally administered medroxyprogesterone acetate suspension.
    Antal EJ; Gillespie WR; Albert KS
    Int J Clin Pharmacol Ther Toxicol; 1983 May; 21(5):257-9. PubMed ID: 6222996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral high-dose medroxyprogesterone acetate (MPA) treatment: cortisol/MPA serum profiles in relation to breast cancer regression.
    Mahlke M; Grill HJ; Knapstein P; Wiegand U; Pollow K
    Oncology; 1985; 42(3):144-9. PubMed ID: 4000617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of carcinoma of the breast with high dose oral medroxyprogesterone acetate: does increased bioavailability improve the therapeutic ratio?
    Roberts JT; Bates T; Bozzino JM; Brock JE; Clarke DG; Durrant KR; Evans RG; Tobias JS
    Clin Oncol (R Coll Radiol); 1990 Nov; 2(6):324-7. PubMed ID: 2149061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medroxyprogesterone acetate and prednisone in advanced breast cancer. A randomized trial.
    Jakobsen A; Frederiksen PL; Møller KA; Andersen AP; Brincker H; Dombernowsky P; Hansen PV; Hesselius I; Kjaer M
    Eur J Cancer Clin Oncol; 1986 Sep; 22(9):1067-72. PubMed ID: 2946583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An evaluation of high-dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast cancer.
    Johnson JR; Priestman TJ; Fotherby K; Kelly KA; Priestman SG
    Br J Cancer; 1984 Sep; 50(3):363-6. PubMed ID: 6235831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate.
    Blossey HC; Wander HE; Koebberling J; Nagel GA
    Cancer; 1984 Sep; 54(6 Suppl):1208-15. PubMed ID: 6088020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The elevation of serum iron level with oral administration of medroxyprogesterone acetate (MPA) in patients with breast cancer].
    Kadota K; Wada T; Watatani M; Houjou T; Mori N; Yasutomi M
    Gan To Kagaku Ryoho; 1991 May; 18(6):983-7. PubMed ID: 1827574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer.
    Falkson G; Falkson HC
    Cancer Chemother Pharmacol; 1983; 11(1):16-8. PubMed ID: 6224603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved bioavailability of a new oral preparation of medroxyprogesterone acetate.
    Etienne MC; Milano G; René N; Benedetti MS; Efthymiopoulos C; Vo Van ML; Hurteloup P; Montcuquet P; Frenay M; Namer M
    J Pharm Sci; 1991 Dec; 80(12):1130-2. PubMed ID: 1839998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [High dose medroxyprogesterone acetate in metastatic breast cancer. Comparative clinical, pharmacokinetic and pharmacodynamic data of different forms of administration].
    Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
    Onkologie; 1982 Aug; 5 Suppl():13-6. PubMed ID: 6215599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific and sensitive determination of medroxyprogesterone acetate in human serum by gas chromatography-mass spectrometry.
    Dikkeschei LD; van Veelen H; Nagel GT; Willemse PH; Wolthers BG
    J Chromatogr; 1985 Nov; 345(1):1-10. PubMed ID: 2935550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral plus intramuscular medroxyprogesterone acetate (high dose Farlutal) in advanced breast cancer.
    Ngelangel CA; Jimenez MV; Villalon AH; Agustin BM
    Southeast Asian J Trop Med Public Health; 1985 Dec; 16(4):634-7. PubMed ID: 2940689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Combination therapy with medroxyprogesterone acetate and tegafur in tamoxifen- and adriamycin-resistant advanced breast cancers].
    Wada T; Matunami N; Houjou T; Morikawa E; Mori N; Nakano K; Aizawa M; Kurooka K; Kadota K; Yamato M
    Gan To Kagaku Ryoho; 1989 May; 16(5):2087-92. PubMed ID: 2525004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [High dose medroxyprogesteroneacetate in metastasizing breast cancer: correlations between course of the disease and hormone profiles].
    Wander HE; Blossey C; Köbberling J; Nagel GA
    Klin Wochenschr; 1983 Jun; 61(11):553-60. PubMed ID: 6224046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical investigation of oral high-dose medroxyprogesterone acetate (MPA) in advanced breast cancer--double-blind controlled study: Japanese Group for MPA Treatment of Breast Cancer].
    Izuo M; Tominaga T; Yoshida M; Nomura Y; Abe O; Enomoto K; Kubo K; Takatani O
    Gan No Rinsho; 1985 May; 31(5):487-93. PubMed ID: 3160869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase III trial of oral high-dose medroxyprogesterone acetate (MPA) versus mepitiostane in advanced postmenopausal breast cancer.
    Izuo M; Yoshida M; Tominaga T; Abe O; Enomoto K; Nomura Y; Kubo K; Takatani O
    Cancer; 1985 Dec; 56(11):2576-9. PubMed ID: 2932213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Therapeutic effects of medroxyprogesterone acetate in recurrent or advanced breast cancer].
    Yoshida M; Murai H; Miura S
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):516-23. PubMed ID: 3159345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant treatment with high dose medroxyprogesterone acetate in node-negative early breast cancer. A 3-year interim report on a randomized trial (I).
    Focan C; Baudoux A; Beauduin M; Bunescu U; Dehasque N; Dewasch L; Lobelle JP; Longeval E; Majois F; Mazy V
    Acta Oncol; 1989; 28(2):237-40. PubMed ID: 2525397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer.
    van Veelen H; Willemse PH; Tjabbes T; Schweitzer MJ; Sleijfer DT
    Cancer; 1986 Jul; 58(1):7-13. PubMed ID: 2939943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.